Search Page

1

Cite

Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment.

Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Wang L, Lim HB, Oh G, Jing X, Beri N, Khanna L, Gonda T, Oberstein P, Hajdu C, Loomis C, Heguy A, Sherman MH, Lund AW, Welling TH, Dolgalev I, Tsirigos A, Simeone DM. Werba G, et al. Among authors: oberstein p. Nat Commun. 2023 Feb 13;14(1):797. doi: 10.1038/s41467-023-36296-4. Nat Commun. 2023. PMID: 36781852 Free PMC article.

Cite

2

Cite

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.

Cite

3

Cite

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ. Rhim AD, et al. Among authors: oberstein pe. Cancer Cell. 2014 Jun 16;25(6):735-47. doi: 10.1016/j.ccr.2014.04.021. Epub 2014 May 22. Cancer Cell. 2014. PMID: 24856585 Free PMC article.

Cite

4

Cite

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.

Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.

Cite

5

Cite

Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness.

Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC. Renz BW, et al. Among authors: oberstein pe. Cancer Discov. 2018 Nov;8(11):1458-1473. doi: 10.1158/2159-8290.CD-18-0046. Epub 2018 Sep 5. Cancer Discov. 2018. PMID: 30185628 Free PMC article.

Cite

6

Cite

Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma.

Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, Sender N, Negri T, Gautier K, Ge L, Fan W, Xie M, Sethi A, Schrope B, Tan AC, Park H, Oberstein PE, Shah MA, Raufi AG. Manji GA, et al. Among authors: oberstein pe. JAMA Oncol. 2023 Dec 1;9(12):1702-1707. doi: 10.1001/jamaoncol.2023.4423. JAMA Oncol. 2023. PMID: 37856106 Free PMC article. Clinical Trial.

Cite

7

Cite

Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.

Peng C, Saffo S, Oberstein PE, Shusterman M, Thomas C, Becker DJ, Berlin JD, Leichman LP, Boursi B, Nagar AB, Yu S. Peng C, et al. Among authors: oberstein pe. J Natl Compr Canc Netw. 2024 Sep 5;22(8):521-527. doi: 10.6004/jnccn.2024.7029. J Natl Compr Canc Netw. 2024. PMID: 39236754

Cite

8

Cite

Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study.

Habib JR, Kinny-Köster B, Javed AA, Zelga P, Saadat LV, Kim RC, Gorris M, Allegrini V, Watanabe S, Sharib J, Arcerito M, Kaiser J, Lafaro KJ, Tu M, Bhandre M, Shi C, Kim MP, Correa C, Daamen LA, Oberstein PE, Schmidt CM, Hanna NN, Allen P, Loos M, Shrikhande SV, Molenaar IQ, Frigerio I, Katz MHG, Soares KC, Miao Y, Del Chiaro M, He J, Hackert T, Salvia R, Büchler MW, Castillo CF, Besselink MG, Marchegiani G, Wolfgang CL; Verona IPMN Consortium. Habib JR, et al. Among authors: oberstein pe. J Clin Oncol. 2024 Dec 20;42(36):4317-4326. doi: 10.1200/JCO.23.02313. Epub 2024 Sep 10. J Clin Oncol. 2024. PMID: 39255450

Cite

9

Cite

Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.

Oberstein PE, Dias Costa A, Kawaler EA, Cardot-Ruffino V, Rahma OE, Beri N, Singh H, Abrams TA, Biller LH, Cleary JM, Enzinger P, Huffman BM, McCleary NJ, Perez KJ, Rubinson DA, Schlechter BL, Surana R, Yurgelun MB, Wang SJ, Remland J, Brais LK, Bollenrucher N, Chang E, Ali LR, Lenehan PJ, Dolgalev I, Werba G, Lima C, Keheler CE, Sullivan KM, Dougan M, Hajdu C, Dajee M, Pelletier MR, Nazeer S, Squires M, Bar-Sagi D, Wolpin BM, Nowak JA, Simeone DM, Dougan SK. Oberstein PE, et al. Cancer Immunol Res. 2024 Sep 3;12(9):1221-1235. doi: 10.1158/2326-6066.CIR-23-1073. Cancer Immunol Res. 2024. PMID: 38990554 Free PMC article. Clinical Trial.

Cite

10

Cite

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study.

Philip PA, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima CMS, Alistar AT, Oberstein PE, Golan T, Metges JP, Lacy J, Fountzilas C, Lopez CD, Ducreux M, Hammel P, Salem M, Bajor D, Benson AB, Luther S, Pardee T, Van Cutsem E. Philip PA, et al. Among authors: oberstein pe. J Clin Oncol. 2024 Nov;42(31):3692-3701. doi: 10.1200/JCO.23.02659. Epub 2024 Aug 1. J Clin Oncol. 2024. PMID: 39088774 Clinical Trial.

Cite